Related Experiment Video
Updated: Apr 12, 2026

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
Published on: December 22, 2023
Pharmacotherapy for inherited arrhythmia syndromes: mechanistic basis, clinical trial evidence and practical
Rafik Tadros1, Julia Cadrin-Tourigny, Sylvia Abadir
1Electrophysiology service and Cardiovascular Genetics Center, Montreal Heart Institute, Université de Montréal, 5000 Bélanger St. E., Montreal, Quebec, H1T 1C8 Canada.
Abstract:
In the absence of structural heart disease, sudden cardiac death is frequently caused by inherited arrhythmia syndromes, such as long QT syndrome, Brugada syndrome and catecholaminergic polymorphic ventricular tachycardia. Managing these conditions often requires a combination of lifestyle modification, pharmacotherapy and less frequently, invasive therapy. Over the past decade, patient management has been greatly enhanced by tailored pharmacotherapy as a result of a deeper appreciation for arrhythmia mechanisms and supportive evidence from multicenter cohort studies. This article reviews current knowledge regarding drug therapy for inherited arrhythmias. Anti-arrhythmic mechanisms and available clinical evidence are highlighted while maintaining a practical perspective on patient management.
Related Concept Videos
Dysrhythmias VI: Management of Dysrhythmias
Mechanism of Cardiac Arrhythmias
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Dysrhythmias V: Evaluating Dysrhythmias

